SCHEMBL14218834

SCHEMBL14218834

CNc1cc(-n2nc(C)cc2Nc2cc(C(=O)Nc3cc(CN(C)c4cc(-n5nc(C)cc5Nc5cc(C(=O)Nc6cc(-n7cnc(C)c7)cc(C(F)(F)F)c6)ccc5C)ncn4)cc(C(F)(F)F)c3)ccc2C)ncn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K2 Q12851 1/20 0.56
EPHB2 P29323 2/20 0.52
KDR P35968 2/20 0.51
LCK P06239 2/20 0.51
LYN P07948 2/20 0.51
HCK P08631 2/20 0.51
SRC P12931 2/20 0.51
INSR P06213 1/20 0.51
ABL1 P00519 8/20 0.50
LDLR P01130 3/20 0.49
KIT P10721 3/20 0.49
PCSK9 Q8NBP7 3/20 0.49
PDGFRB P09619 2/20 0.49
BCR P11274 5/20 0.48
ADORA3 P0DMS8 2/20 0.48
NR1I2 O75469 1/20 0.48
PTGS1 P23219 1/20 0.48
CHRNA4 P43681 1/20 0.48
PDE3A Q14432 1/20 0.48
BRAF P15056 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580903 0.91 MAP4K2 (0.65) MAP4K2EPHB2KDRLCKLYN
SCHEMBL3590408 0.87 BRAF (0.47) MAP4K2KDRLCKLYNHCK
SCHEMBL3582693 0.83 CSF1R (0.58) MAP4K2EPHB2KDRLCKLYN
SCHEMBL3592374 0.83 MAP4K2 (0.55) MAP4K2EPHB2KDRLCKLYN
SCHEMBL3594586 0.81 MAP4K2 (0.49) MAP4K2KDRLCKLYNHCK
SCHEMBL3589389 0.80 MAP4K2 (0.48) MAP4K2KDRLCKLYNHCK
SCHEMBL3591101 0.80 BRAF (0.54) MAP4K2HCKBRAFMAPK14DDR2
SCHEMBL3592154 0.80 BRAF (0.58) ABL1BRAF
SCHEMBL3585221 0.80 BRAF (0.51) ABL1BRAF
SCHEMBL3583692 0.80 BRAF (0.61) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO disclosed